SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
Abroad (travel likely)RecruitingPHASE3
Conditions
Non-small Cell Lung Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Shanghai Pulmonary Hospital, Shanghai, Shanghai Municipality, China
Study leads
Caicun Zhou, Professor
Principal Investigator
Shanghai Pulmonary Hospital, Shanghai, China
Daqiang Sun, Professor
Principal Investigator
Tianjin Chest Hospital, Tianjin, China